1. Home
  2. PDT vs YDES Comparison

PDT vs YDES Comparison

Compare PDT & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Premium Dividend Fund

PDT

John Hancock Premium Dividend Fund

HOLD

Current Price

$13.01

Market Cap

653.2M

Sector

Finance

ML Signal

HOLD

YDES

YD Bio Limited Ordinary Shares

HOLD

Current Price

$1.98

Market Cap

543.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDT
YDES
Founded
N/A
2013
Country
United States
Taiwan
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
653.2M
543.0M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
PDT
YDES
Price
$13.01
$1.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
129.0K
308.1K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.53
$1.70
52 Week High
$13.65
$25.00

Technical Indicators

Market Signals
Indicator
PDT
YDES
Relative Strength Index (RSI) 62.46 34.14
Support Level $13.03 N/A
Resistance Level $13.18 $5.36
Average True Range (ATR) 0.13 0.54
MACD 0.04 0.02
Stochastic Oscillator 100.00 18.75

Price Performance

Historical Comparison
PDT
YDES

About PDT John Hancock Premium Dividend Fund

John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Share on Social Networks: